Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the February 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay, ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer PFE we detected 13 trades. If we consider the specifics of each trade, it is ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent ...